Trial reportJournal of cardiothoracic surgery2025
Low-dose nicardipine during cardiopulmonary bypass improves carotid hemodynamics in CABG patients: a randomized controlled trial.
Trial report in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPostoperative cognitive dysfunction (POCD) is a common complication of coronary artery bypass grafting (CABG) with cardiopulmonary bypass (CPB), largely associated with cerebral hemodynamic disturbances. Carotid duplex ultrasonography–derived parameters, including peak systolic velocity (PSV-ICA) and end-diastolic velocity (EDV-ICA), provide reliable, noninvasive indicators of cerebral blood flow. This study evaluated whether intraoperative nicardipine infusion improves carotid blood flow and mitigates postoperative cognitive decline.
methodsIn this randomized, double-blind trial, 64 elderly patients undergoing CABG were assigned to receive either continuous low-dose nicardipine (0.2–0.5 µg/kg·min) during CPB (nicardipine group, n = 32) or saline (control group, n = 32). The co-primary endpoints were intraoperative PSV-ICA and EDV-ICA at four predefined time points (T1: pre-anesthesia; T2: surgery initiation; T3: during CPB; T4: post-CPB). Secondary endpoints included regional cerebral oxygen saturation (rScO₂), plasma neuron-specific enolase (NSE), Mini-Mental State Examination (MMSE) scores, vasopressor use, ventilation time, ICU stay, and hospitalization length.
resultsBaseline and intraoperative characteristics were comparable. Both groups showed reduced carotid flow velocities during CPB, but recovery of PSV-ICA at the end of CPB was significantly greater with nicardipine (63.7 ± 15.2 vs. 54.3 ± 13.9 cm/s; P = 0.025). EDV-ICA exhibited a similar trend without significant between-group differences. Secondary outcomes (MMSE, NSE) did not differ, and no adverse events occurred.
conclusionContinuous low-dose nicardipine during CPB significantly improved the recovery of PSV-ICA without affecting systemic hemodynamics or increasing adverse events. These findings suggest a potential intraoperative neuroprotective role of nicardipine, warranting confirmation in larger trials with long-term cognitive outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.